- Home
- BFRG vs LGVN Comparison
BFRG vs LGVN Comparison
Compare BFRG & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRG
- LGVN
- Stock Information
- Founded
- BFRG 2017
- LGVN 2014
- Country
- BFRG United States
- LGVN United States
- Employees
- BFRG 17
- LGVN N/A
- Industry
- BFRG Retail: Computer Software & Peripheral Equipment
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- BFRG Technology
- LGVN Health Care
- Exchange
- BFRG Nasdaq
- LGVN Nasdaq
- Market Cap
- BFRG 15.4M
- LGVN 16.4M
- IPO Year
- BFRG 2023
- LGVN 2021
- Fundamental
- Price
- BFRG $1.49
- LGVN $0.80
- Analyst Decision
- BFRG
- LGVN Strong Buy
- Analyst Count
- BFRG 0
- LGVN 2
- Target Price
- BFRG N/A
- LGVN $6.50
- AVG Volume (30 Days)
- BFRG 139.3K
- LGVN 330.0K
- Earning Date
- BFRG 11-07-2025
- LGVN 11-11-2025
- Dividend Yield
- BFRG N/A
- LGVN N/A
- EPS Growth
- BFRG N/A
- LGVN N/A
- EPS
- BFRG N/A
- LGVN N/A
- Revenue
- BFRG $33,257.00
- LGVN $2,073,000.00
- Revenue This Year
- BFRG N/A
- LGVN N/A
- Revenue Next Year
- BFRG N/A
- LGVN N/A
- P/E Ratio
- BFRG N/A
- LGVN N/A
- Revenue Growth
- BFRG N/A
- LGVN 68.67
- 52 Week Low
- BFRG $1.09
- LGVN $0.63
- 52 Week High
- BFRG $4.84
- LGVN $2.48
- Technical
- Relative Strength Index (RSI)
- BFRG 59.62
- LGVN 45.30
- Support Level
- BFRG $1.32
- LGVN $0.73
- Resistance Level
- BFRG $1.53
- LGVN $0.82
- Average True Range (ATR)
- BFRG 0.10
- LGVN 0.03
- MACD
- BFRG 0.01
- LGVN 0.02
- Stochastic Oscillator
- BFRG 76.00
- LGVN 71.89
About BFRG Bullfrog AI Holdings Inc.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.